Authors
Jelena Čelutkienė, Radek Pudil, Teresa López‐Fernández, Julia Grapsa, Petros Nihoyannopoulos, Jutta Bergler‐Klein, Alain Cohen‐Solal, Dimitrios Farmakis, Carlo Gabriele Tocchetti, Stephan von Haehling, Vassilis Barberis, Frank A Flachskampf, Indrė Čeponienė, Eva Haegler‐Laube, Thomas Suter, Tomas Lapinskas, Sanjay Prasad, Rudolf A de Boer, Kshama Wechalekar, Markus S Anker, Zaza Iakobishvili, Chiara Bucciarelli‐Ducci, Jeanette Schulz‐Menger, Bernard Cosyns, Oliver Gaemperli, Yury Belenkov, Jean‐Sébastien Hulot, Maurizio Galderisi, Patrizio Lancellotti, Jeroen Bax, Thomas H Marwick, Ovidiu Chioncel, Tiny Jaarsma, Wilfried Mullens, Massimo Piepoli, Thomas Thum, Stephane Heymans, Christian Mueller, Brenda Moura, Frank Ruschitzka, Jose Luis Zamorano, Giuseppe Rosano, Andrew JS Coats, Riccardo Asteggiano, Petar Seferovic, Thor Edvardsen, Alexander R Lyon
Publication date
2020/9
Journal
European journal of heart failure
Volume
22
Issue
9
Pages
1504-1524
Publisher
John Wiley & Sons, Ltd.
Description
Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio‐Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio‐oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three‐dimensional ejection fraction, are proposed. The protocol for baseline pre‐treatment evaluation and specific …
Scholar articles
J Čelutkienė, R Pudil, T López‐Fernández, J Grapsa… - European journal of heart failure, 2020